NDA 209569 · Dutch Ophthalmic
Tissueblue
Brilliant Blue G · Ophthalmic · Disclosing Agent
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Dec 20, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
21
16 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 17, 2026.
Indications & Usage TissueBlue 0.025% is indicated to selectively stain the internal limiting membrane (ILM). TissueBlue 0.025% is a disclosing agent indicated to selectively stain the internal limiting membrane (ILM).
Mechanism: Mechanism of action Brilliant Blue G has been shown to selectively stain the ILM, but not the epiretinal membrane nor the retina, making it easier to visualize the membrane for removal, although the exact mechanism of this selectivity has not been elucidated.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- TISSUEBLUE · BRILLIANT BLUE G 0.025% · SOLUTION, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Brilliant Blue G" as an intervention, any sponsor and status, largest first.
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT03020459 · 30 participants · Start Jan 1, 2017 · Primary completion Jul 30, 2019
Drug: Brilliant Blue G · For: Macular Hole; Surgery
Sites: Shanghai, China
- Safety and Efficacy of Double Staining With Brilliant Blue G for Macular SurgeryPivotal-lookingTerminated
Asociación para Evitar la Ceguera en MéxicoAcademic, hospital or other
NCT01820520 · 22 participants · Start Jan 2013 · Primary completion Feb 2014
Drug: brilliant blue G · For: Macular Hole; Epiretinal Membrane
Sites: Mexico City, Mexico
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- disability3
- visual impairment3
- blindness2
- non-infectious endophthalmitis2
- toxic anterior segment syndrome2
- adverse drug reaction1
- drug hypersensitivity1
- endophthalmitis1
- eye disorder1
- eye injury1
- hemianopia1
- impaired quality of life1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- BRILLIANT BLUE G-ASSISTED INTERNAL LIMITING MEMBRANE PEELING FOR MACULAR HOLE: A Systematic Review of Literature and Meta-Analysis.
Azuma K, Noda Y, Hirasawa K, et al. · Retina 2016 · Meta-Analysis, Systematic Review
- Histopathological Analysis of Internal Limiting Membrane Surgically Peeled From Eyes with Epiretinal Membrane.
Beyazyildiz Ö, Tirhiş MH, Hekimoğlu ER, et al. · Curr Eye Res 2016 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling.
Enaida H, Hisatomi T, Hata Y, et al. · Retina 2006 · Clinical Trial, Research Support, Non-U.S. Gov't
- Use of Brilliant Blue G in Descemet's Membrane Endothelial Keratoplasty.
Hayashi T, Yuda K, Oyakawa I, et al. · Biomed Res Int 2017 · Clinical Trial, Comparative Study
- Influence of the thickness of mineral trioxide aggregate on sealing ability of root-end fillings in vitro.
Valois CR, Costa ED · Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004 · Clinical Trial, Comparative Study
- Comparison of trypan blue and Brilliant Blue G for staining of the anterior lens capsule during cataract surgery: short-term results.
Nagashima T, Yuda K, Hayashi T · Int Ophthalmol 2019 · Randomized Controlled Trial
Sponsor: Dutch Ophthalmic
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.